His tumor DNA extracted from the tissue was subjected to DNA sequencing analysis, with genetic testing revealing that the patient had an EGFR exon 21 mutation (c.2573 T>G, p.Leu858Arg 10.5%), MEK1 exon 3 mutation (c.335T>C, p.lle112Thr 40.3%), and a high PD-L1 expression[tumor proportion score (TPS) = 95%]. This evidence concerns the gene MAP2K1 and neoplasm.